Stock Financial Ratios, Dividends, Split History

HEP / Holly Energy Partners L.P. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price29.39
Volume170,500.00
Market Cap ($M)3,093.85
Enterprise Value ($M)4,689.18
Book Value / Share4.61
Price / Book6.43
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 105,268,955
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.10
Return on Assets (ROA)0.11
Return on Equity (ROE)0.43
Balance Sheet (mrq) ($M)
Assets2,154.11
Liabilities1,669.05
Quick Ration/a
Current Ratio1.34
Income Statement (mra) ($M)
Operating Income223.16
Net Income201.91
Cash Flow Statement (mra) ($M)
Cash From Operations238.49
Cash from Investing-286.27
Cash from Financing-286.27
Identifiers and Descriptors
CUSIP435763107
Central Index Key (CIK)1283140
Related CUSIPS
435763957 435763907

Split History

Stock splits are used by Holly Energy Partners L.P. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

'Safer' Dividend Contenders, Show Positive Annual Returns, Cash For Dividends, And 10-24 Years Of Increases

2018-05-09 seekingalpha
25 of 80 Dividend Contenders (10-24 annual dividend hikes) were tagged as 'safer' because they showed positive annual-returns, and free cash-flow yields higher than their dividend yields 5/7/18. (39-0)

30 Dividend Contenders Show 4.68-12.91% Yields Backed By 10-24 Years Of Increases

2018-05-09 seekingalpha
Broker target-estimated May Dividend Contender top-ten net-gains ranged 20%-43.7%, from BIP, QCOM, TCP, EPD, ENB, ETE, SEP, PM, TLP, and were topped by ETP as selected 4/30/18 and measured 5/7/18. (45-0)

30 Dividend Contenders Show 4.68%-12.91% Yields Backed By 10-24 Years Of Increases

2018-05-09 seekingalpha
Broker target-estimated May Dividend Contender top-ten net-gains ranged 20%-43.7%, from BIP, QCOM, TCP, EPD, ENB, ETE, SEP, PM, TLP, and were topped by ETP as selected 4/30/18 and measured 5/7/18. (45-0)

HollyFrontier (HFC) Q1 Earnings Surpass on Higher Margins

2018-05-08 zacks
HollyFrontier Corporation (HFC - Free Report) reported first-quarter 2018 net income per share (excluding special items) of 77 cents, significantly above the Zacks Consensus Estimate of 37 cents. The better-than-anticipated results can be attributed to higher-than-expected refining margins and refined product sales. Notably, the refining margins in the quarter stood at $12.83 a barrel compared with the Zacks Consensus Estimate of $10. (7-0)

54 Straight Hikes, A 9% Yield, No IDRs For This Blue-Chip LP

2018-05-06 seekingalpha
An expansion project in the western Permian Basin is due to come online in Q4 '18. (2-0)

CUSIP: 435763107